Learn about progress on health equity and anti-racism efforts in Seattle Children’s fourth quarterly report.

Current Research Studies

Cancer – ADVL1614: Phase 1/2 Study of VX26/3604 in Children, Adolescents or Young Adults with Recurrent or Relapsed Solid Tumors

Condition or Therapy:

Solid tumors

Category:

Cancer and Blood Disorders
Study Number: ADVL1614

What is the goal of this study?

Researchers want to assess the maximum tolerated dose of pepinemab to be given to children with recurrent or refractory solid tumors.

Who can join the study?

This study may be a good fit for children and young adults who:

are between 1 and 30 years old, and
have recurrent or refractory solid tumors or osteosarcoma.

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106, or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Looking for a Researcher?

Name: First Name Last Name
Area of Focus: Research Center:

©1995–2022 Seattle Children’s Hospital

4800 Sand Point Way NE,

Seattle,

WA

98105

206-987-2000

866-987-2000 (toll-free)

206-987-0391 (TTY)

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.